qz
Eli Lilly is acquiring blood cancer drug developer Ajax Therapeutics for up to $2.3 billion

The deal centers on AJ1-11095, a first-in-class experimental oral drug in early-stage trials for myelofibrosis patients [...]

Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

Destination
Eli Lilly signs $2.75 billion deal with AI drug developer Insilico Medicine

US pharmaceutical giant Eli Lilly is betting big on AI-driven drug development, signing a $2.75 billion deal with Hong Kong-listed Insilico Medicine.<br /> The article Eli Lilly signs $2.75 bill [...]

Match Score: 115.52

Destination
FDA approves at-home pap smear alternative device for cervical cancer screening

The Food and Drug Administration has approved a new device called the Teal Wand, which its creator describes as an "at-home vaginal sample self-collection device for cervical cancer screening.&qu [...]

Match Score: 96.08

Destination
Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — and Eli Lilly’s drug came out on top.Read more... [...]

Match Score: 96.04

qz
Eli Lilly is buying cancer biotech Kelonia Therapeutics for more than $2 billion

The deal expands Lilly's in vivo CAR-T cancer therapy pipeline, anchored by a multiple myeloma drug that showed early clinical results [...]

Match Score: 81.93

Destination
An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as it would be easier to manufacture and distribute globally. Three U.S. sen [...]

Match Score: 76.59

Destination
Eli Lilly's online health platform just expanded beyond weight loss to tackle Alzheimer’s

Just about a year after launching a direct-to-consumer online platform to sell treatments for diabetes and obesity, Eli Lilly (LLY) is now expanding the program to offer resources for Alzheimer’s d [...]

Match Score: 76.59

qz
Eli Lilly looks beyond GLP-1s with a $3 billion cancer buy

Eli Lilly announced it will acquire Kelonia Therapeutics for $3.25 billion upfront to expand its oncology and genetic medicines pipeline [...]

Match Score: 71.99

Destination
Eli Lilly's Alzheimer's drug is rejected by EU regulators over brain swelling risk, despite U.S. approval

The European Union’s health regulator on Friday rejected Eli Lilly’s (LLY) Alzheimer’s drug, Kisunla, citing risks of brain swelling and bleeding. It’s a major setback for the company as it co [...]

Match Score: 71.00

Destination
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous w [...]

Match Score: 66.87